Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial of Ropinirole in Motor Recovery After Stroke

This study has been completed.
Information provided by:
University of California, Irvine Identifier:
First received: September 19, 2005
Last updated: June 19, 2008
Last verified: June 2008

September 19, 2005
June 19, 2008
October 2003
February 2007   (final data collection date for primary outcome measure)
Not Provided
gait velocity
Complete list of historical versions of study NCT00221390 on Archive Site
  • Barthel Index [ Time Frame: Measured at weeks 1, 9, and 12 ] [ Designated as safety issue: Yes ]
  • Leg motor Fugl-Meyer scale [ Time Frame: Measured at baseline and weeks 1, 2, 4, 6, 7, 8, 9, and 12 ] [ Designated as safety issue: Yes ]
  • Stroke Impact Scale-16 [ Time Frame: Measured at weeks 1, 4, 7, 9, and 12 ] [ Designated as safety issue: Yes ]
  • Gait endurance [ Time Frame: Measured at weeks 1, 2, 4, 6, 7, 8, 9, and 12 ] [ Designated as safety issue: Yes ]
  • Hamilton Depression Scale [ Time Frame: Measured at baseline and weeks 1, 2, 9, and 12 ] [ Designated as safety issue: Yes ]
  • Safety [ Time Frame: 12 weeks ] [ Designated as safety issue: Yes ]
  • Barthel Index
  • Leg motor Fugl-Meyer scale
  • Stroke Impact Scale-16
  • Gait endurance
  • Hamilton Depression Scale
  • Safety
Not Provided
Not Provided
Trial of Ropinirole in Motor Recovery After Stroke
Randomized, Placebo-Controlled, Double-Blind Pilot Trial to Evaluate the Safety and Efficacy of Ropinirole in Motor Recovery After Stroke
The purpose of this study is to assess efficacy, as well as safety, of Ropinirole in improving movement among patients with chronic stroke.
Stroke is a leading cause of disability. Current treatments target injury and must be delivered within hours. A body of literature suggests that there are processes ongoing days-months after stroke that can be targeted therapeutically, and improve function. The current study evaluates one such potential therapy, the dopamine agonist ropinirole. The current study tests the hypothesis that patients with chronic stroke randomized to ropinirole+physiotherapy will show improved gait velocity over the 12 weeks of study participation as compared to patients randomized to placebo+physiotherapy. A secondary aim is to test the hypothesis that ropinirole will improve three secondary endpoints at 12 weeks after study entry: the proportion of patients with no significant disability (Barthel Index ≥ 95); overall motor status, measured with the arm/leg FM score; and overall physical function, defined as the score on the Stroke Impact Scale-16 (SIS-16). This study will also evaluate the safety of ropinirole in patients recovering from stroke.
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Cerebrovascular Accident
  • Hemiparesis
  • Drug: Ropinirole (+ physical therapy)
  • Drug: (vs.) Placebo + physical therapy
Not Provided
  • 1. Gresham GE, Duncan PW, Stason WB, Adams HP, Adelman AM, Alexander DN, Bishop DS, Diller L, Donaldson NE, Granger CV, Holland AL, Kelly-Hayes M, McDowell FH, Myers L, Phipps MA, Roth EJ, Siebens HC, Tarvin GA, Trombly CA. Post-Stroke Rehabilitation. Rockville, MD: U.S. Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research, 1995. 2. Rathore SS, Hinn AR, Cooper LS, Tyroler HA, Rosamond WD. Characterization of incident stroke signs and symptoms: findings from the atherosclerosis risk in communities study. Stroke 2002;33:2718-21. 3. Dobkin BH. Neurologic Rehabilitation. Philadelphia: FA Davis, 1996. 4. Nudo RJ. Recovery after damage to motor cortical areas. Curr Opin Neurobiol 1999;9:740-7. 5. Cramer SC, Chopp M. Recovery recapitulates ontogeny. Trends Neurosci 2000;23:265-71. 6. Finklestein S, Campbell A, Baldessarini RJ, Moya KL, Haber SN. Late changes in cerebral monoamine metabolism following focal ventrolateral cerebrocortical lesions in rats. Brain Res 1985;344:205-10. 7. Finklestein S, Campbell A, Stoll AL, Baldessarini RJ, Stinus L, Paskevitch PA, Domesick VB. Changes in cortical and subcortical levels of monoamines and their metabolites following unilateral ventrolateral cortical lesions in the rat. Brain Res 1983;271:279-88. 8. Boyeson MG, Feeney DM. Striatal dopamine after cortical injury. Exp Neurol 1985;89:479-83. 9. Stroemer RP, Kent TA, Hulsebosch CE. Enhanced neocortical neural sprouting, synaptogenesis, and behavioral recovery with D-amphetamine therapy after neocortical infarction in rats. Stroke 1998;29:2381-95. 10. Cramer SC, Nelles G, Benson RR, Kaplan JD, Parker RA, Kwong KK, Kennedy DN, Finklestein SP, Rosen BR. A functional MRI study of subjects recovered from hemiparetic stroke. Stroke 1997;28:2518-27. 11. Feeney DM, Gonzalez A, Law WA. Amphetamine, Halperidol, and experience interact to affect the rate of recovery after motor cortex injury. Science 1982;217:855-857. 12. Gladstone DJ, Black SE. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can J Neurol Sci 2000;27:97-105. 13. Goldstein LB. Potential impact of drugs on poststroke motor recovery. In: L. B. Goldstein, ed. Restorative Neurology. Advances in pharmacotherapy for recovery after stroke. Armonk, NY: Futura Publishing Co., 1998:241-256. 14. Scheidtmann K, Fries W, Muller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet 2001;358:787-790. 15. Sullivan KJ, Knowlton BJ, Dobkin BH. Step training with body weight support: effect of treadmill speed and practice paradigms on poststroke locomotor recovery. Arch Phys Med Rehabil 2002;83:683-91. 16. Richards C, Malouin F, Dumas F, Tardif D. Gait velocity as an outcome measure of locomotor recovery after stroke. In: C. R and O. C, eds. Gait Analysis: Theory and Application. St. Louis: Mosby, 1995:355-364. 17. Potter JM, Evans AL, Duncan G. Gait speed and activities of daily living function in geriatric patients. Arch Phys Med Rehabil 1995;76:997-9. 18. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53-83. 19. Medico M, De Vivo S, Tomasello C, Grech M, Nicosia A, Castorina M, D'Agata MA, Rampello L, Lempereur L, Drago F. Behavioral and neurochemical effects of dopaminergic drugs in models of brain injury. Eur Neuropsychopharmacol 2002;12:187-94. 20. Bracha HS, Lyden PD, Khansarinia S. Delayed emergence of striatal dopaminergic hyperactivity after anterolateral ischemic cortical lesions in humans; evidence from turning behavior. Biol Psychiatry 1989;25:265-74. 21. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
  • Cramer SC, Dobkin BH, Noser EA, Rodriguez RW, Enney LA. Randomized, placebo-controlled, double-blind study of ropinirole in chronic stroke. Stroke. 2009 Sep;40(9):3034-8. doi: 10.1161/STROKEAHA.109.552075. Epub 2009 Jun 11.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2007
February 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Stroke onset 4 weeks-12 months prior
  2. Stroke is radiologically confirmed as either (a) ischemic or (b) hemorrhagic
  3. Minimum age 18
  4. No significant pre-stroke disability
  5. No other stroke in previous 3 months
  6. Absence of major depression
  7. Fugl-Meyer (FM) motor score of 23-83 out of 100
  8. Functional Independence Measure (FIM) ambulation-subscore of 3 or more, and 50 foot walk takes longer than 15 seconds

Exclusion Criteria:

  1. Significant daytime somnolence or any substantial decrease in alertness, language reception, or attention
  2. Pregnant or lactating
  3. Advanced liver, kidney, cardiac, or pulmonary disease
  4. Orthostatic hypotension
  5. Current use of ciprofloxacin, a centrally acting dopamine agonist, or a centrally active dopamine antagonist
  6. A terminal medical diagnosis consistent with survival < 1 year
  7. Coexistent major neurological disease
  8. Coexistent major psychiatric disease
  9. A history of significant alcohol or drug abuse in the prior 3 years
  10. A coexistent disease characterized by an abnormality of CNS dopaminergic tone
  11. Current enrollment in another investigational study related to stroke or stroke recovery
  12. Contraindication to ropinirole prescription
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Steven C. Cramer, MD, MMSc, University of California, Irvine
University of California, Irvine
Principal Investigator: Steven C Cramer, MD University of California, Irvine
University of California, Irvine
June 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP